Novo Nordisk rose about 3% after Phase 3 data showed CagriSema cut body weight by roughly 21% over 68 weeks, with a US regulatory decision due this quarter.
- Novo Nordisk (NVO) shares gained about 3% on the CagriSema Phase 3 results.
- CagriSema reduced body weight by roughly 21% over 68 weeks.
- A US regulatory decision on the obesity drug is expected in the fourth quarter of 2026.
Lead
Novo Nordisk (NYSE: NVO) shares rose about 3% on Monday after Phase 3 trial data showed its experimental obesity drug CagriSema reduced body weight by roughly 21% over 68 weeks. A US regulatory decision is expected this quarter, giving the Danish drugmaker a near-term catalyst in its contest with Eli Lilly (LLY) for the obesity market.What Did the CagriSema Phase 3 Data Show?
The trial showed CagriSema produced average weight loss of roughly 21% over 68 weeks. The figure puts the drug among the most effective obesity treatments tested in late-stage studies.
CagriSema is a once-weekly injection that combines two compounds. Semaglutide, the active ingredient in Novo's Wegovy and Ozempic, mimics the gut hormone GLP-1 to suppress appetite. Cagrilintide mimics amylin, a hormone that also regulates appetite and satiety. Pairing the two is designed to deliver more weight loss than semaglutide alone, which has been the commercial backbone of Novo's obesity franchise.
Why Did Novo Nordisk Shares Rise About 3%?
Shares rose because the data supports Novo's effort to build a next-generation obesity portfolio as competition intensifies. The 21% figure narrows the efficacy gap with Lilly's tirzepatide, sold as Zepbound and Mounjaro, which has taken a growing share of new US prescriptions.
Novo has faced pricing pressure, slower growth in its flagship franchise and a reset in investor expectations. A positive late-stage readout on a follow-on product addresses a central concern: whether the company can defend its position once semaglutide faces more competition. The move registered across large-cap drug stocks that anchor any pharma etf, though the gain in Novo outpaced the sector.
How Does CagriSema Fit Novo's Strategy?
CagriSema is the company's main bet on holding a leading position in obesity as the market expands beyond injectables to oral and combination therapies. Success depends on three factors: efficacy relative to tirzepatide, tolerability, and the ability to supply a large patient base.
The US is the largest and highest-priced market for obesity drugs. Approval would let Novo offer a second, higher-efficacy product alongside Wegovy, potentially retaining patients who might otherwise switch to a competitor. Coverage by insurers and employer plans remains a constraint on volume across the category, and pricing for the class continues to come under scrutiny from US payers and policymakers.
What Comes Next for CagriSema in the US?
The next step is the US regulatory decision, expected this quarter. An approval would move CagriSema from late-stage trials to commercial launch, with attention shifting to labeling, pricing and payer coverage.
A delay or a restrictive label would weigh on sentiment, given the stock's reaction to the trial data. Investors will also watch for updates on manufacturing capacity, which constrained supply of GLP-1 drugs during the earlier phase of demand growth. Lilly's pipeline, including next-generation candidates, sets the competitive benchmark against which CagriSema will be measured.
Outlook
Novo Nordisk gained about 3% as the CagriSema Phase 3 results, a roughly 21% weight reduction over 68 weeks, strengthened the case for its obesity pipeline. The US decision this quarter is the next test, and the outcome will shape how the company competes with Lilly in a market where efficacy, supply and payer coverage determine share.





